<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) are <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> of the gastrointestinal tract </plain></SENT>
<SENT sid="1" pm="."><plain>While a cure remains elusive, both can be treated with medications that induce and maintain remission </plain></SENT>
<SENT sid="2" pm="."><plain>With the recent advent of therapies that inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:chebi fb="0" ids="6775">5-ASA</z:chebi> agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal </plain></SENT>
<SENT sid="4" pm="."><plain>Antibiotics may have a limited role in the treatment of colonic CD </plain></SENT>
<SENT sid="5" pm="."><plain>Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non-systemic steroids such as oral and rectal <z:chebi fb="0" ids="3207">budesonide</z:chebi> for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> (<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi>) and its <z:chebi fb="0" ids="50266">prodrug</z:chebi> <z:chebi fb="2" ids="2948">azathioprine</z:chebi> are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while <z:chebi fb="0" ids="44185">methotrexate</z:chebi> may be used in both induction and maintenance of CD </plain></SENT>
<SENT sid="7" pm="."><plain>Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, and infliximab is also approved for the treatment of UC </plain></SENT>
</text></document>